PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
5.92%
Net income growth under 50% of AVGO's 84.13%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-2.17%
Negative yoy D&A while AVGO is 7.09%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-700.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
10.29%
SBC growth well above AVGO's 6.93%. Michael Burry would flag major dilution risk vs. competitor’s approach.
17.19%
Well above AVGO's 33.71% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
-94.12%
Both yoy AR lines negative, with AVGO at -153.85%. Martin Whitman would suspect an overall sector lean approach or softer demand.
-96.23%
Both reduce yoy inventory, with AVGO at -52.31%. Martin Whitman would find a widespread caution or cyclical demand drop in the niche.
115.38%
AP growth well above AVGO's 16.79%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
38.49%
Lower 'other working capital' growth vs. AVGO's 94.79%. David Dodd would see fewer unexpected short-term demands on cash.
131.25%
Some yoy increase while AVGO is negative at -80.72%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
15.35%
Operating cash flow growth similar to AVGO's 17.00%. Walter Schloss would see parallel improvements or market conditions in cash generation.
-18.90%
Negative yoy CapEx while AVGO is 21.23%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
-49.27%
Negative yoy purchasing while AVGO stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
12.95%
Liquidation growth of 12.95% while AVGO is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-561.29%
Both yoy lines negative, with AVGO at -4900.00%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-103.00%
Both yoy lines negative, with AVGO at -54.55%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
-50.00%
We cut debt repayment yoy while AVGO is 98.20%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-47.83%
Negative yoy issuance while AVGO is 45.90%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-18.18%
We cut yoy buybacks while AVGO is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.